Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.84 |
| ▸ | IGF1R | P08069 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL29588563 | 1.00 | EGFR (0.84) | EGFRKCNH2IGF1R | |
| SCHEMBL22695155 | 1.00 | EGFR (0.84) | EGFRKCNH2IGF1R | |
| Hydrochloric Acid SCHEMBL29588253 | 0.99 | EGFR (0.83) | EGFRKCNH2IGF1R | |
| Glycine SCHEMBL29588700 | 0.96 | EGFR (0.78) | EGFRKCNH2IGF1R | |
| SCHEMBL30017478 | 0.96 | EGFR (0.78) | EGFRKCNH2IGF1R | |
| SCHEMBL22689239 | 0.95 | EGFR (0.83) | EGFRKCNH2IGF1R | |
| SCHEMBL29588254 | 0.95 | EGFR (0.83) | EGFRKCNH2IGF1R | |
| SCHEMBL28942055 | 0.94 | EGFR (0.74) | EGFRKCNH2IGF1R | |
| Hippuric Acid SCHEMBL29588378 | 0.93 | EGFR (0.73) | EGFRKCNH2IGF1R | |
| SCHEMBL22695172 | 0.93 | EGFR (0.72) | EGFRKCNH2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340547-A1 | INDOLE DERIVATIVE-CONTAINING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-10-27 | — | — | US | disclosed |
| WO-2022105882-A1 | SALT AND CRYSTAL FORM OF INDOLE-CONTAINING DERIVATIVE, AND PREPARATION METHODS THEREFOR AND APPLICATIONS THEREOF | 上海翰森生物医药科技有限公司 | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340547-A1 | INDOLE DERIVATIVE-CONTAINING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ERBB2, EGFR, ABL1 | EGFR 2/4885KCNH2 3796/4885IGF1R 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.